Form 4: Arcus Biosciences Chief Accounting Officer Sells Shares Under 10b5-1 Plan

Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, sold 3,007 shares of common stock at $15.17 per share on December 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Alexander Azoy, the Chief Accounting Officer of Arcus Biosciences, sold 3,007 shares of common stock on December 19, 2024.
• The sale was executed at a price of $15.17 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on May 10, 2024.
• Following the transaction, Azoy directly owns 13,094 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company executive under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that the sale was executed under a 10b5-1 plan suggests it was pre-planned and not based on any specific inside information at the time of the transaction.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates